FDA approves Moderna’s mRNA flu vaccine for adults 50–64 and accelerates approval for 65+
The story in brief
On 5 August, the FDA approved Moderna’s mRNA-based flu vaccine mFLUSIVA for adults aged 50–64 and granted accelerated approval for those 65 and older. The vaccine, which uses mRNA to target the flu virus’s hemagglutinin protein, showed a 26.6% relative reduction in confirmed flu cases compared to standard vaccines. Moderna plans to roll it out for the 2026–27 flu season in the U.S. in a few weeks.